TAE Life Sciences is pioneering advancements in biologically targeted radiation therapy, specifically through the development of boron neutron capture therapy (BNCT). This innovative approach utilizes boron-10 drugs that are selectively absorbed by cancer cells. When these cells are exposed to a low-energy neutron beam, a reaction occurs that emits alpha particles, effectively destroying the tumor cells while minimizing damage to surrounding healthy tissues. BNCT is particularly promising for treating aggressive and difficult-to-manage cancers, such as glioblastoma and recurrent head and neck cancers, and can often be administered in just one or two treatment sessions, significantly enhancing patient quality of life compared to traditional therapies.

The company has also developed the Alphabeam™ Neutron System, which leverages advancements in particle accelerators to provide a compact, in-hospital neutron source. This system addresses historical challenges associated with the accessibility of safe and effective neutron sources for clinical use, allowing for the installation of BNCT technology in existing hospital facilities. With a growing number of BNCT centers worldwide and increasing clinical evidence supporting its efficacy, TAE Life Sciences is at the forefront of making this targeted therapy a standard option for patients with hard-to-treat malignancies.

United States

TAE Life Sciences uses Boron Neutron Capture Therapy (BNCT) to provide a treatment option for patients with malignancies that are difficult to treat through traditional methods, such as head, neck and brain cancers.

TAE Life Sciences

Company Details